Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Future directions in plasminogen activator therapy.

C Bode1, M S Runge, E Haber

  • 1Medical Clinic III (Cardiology), University of Heidelberg, Federal Republic of Germany.

Clinical Cardiology
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Usability and feasibility of E-nergEYEze: a blended vision-specific E-health based cognitive behavioral therapy and self-management intervention to reduce fatigue in adults with visual impairment.

BMC health services research·2023
Same author

Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.

West African journal of medicine·2023
Same author

The effectiveness of motivational interviewing on adherence to wearing orthopedic shoes in people with diabetes at low-to-high risk of foot ulceration: A multicenter cluster-randomized controlled trial.

Diabetes research and clinical practice·2023
Same author

Attitudes and experiences towards the application of motivational interviewing by podiatrists working with people with diabetes at high-risk of developing foot ulcers: a mixed-methods study.

Journal of foot and ankle research·2022
Same author

Using motivational interviewing combined with digital shoe-fitting to improve adherence to wearing orthopedic shoes in people with diabetes at risk of foot ulceration: study protocol for a cluster-randomized controlled trial.

Trials·2021
Same author

Pro- and anti-inflammatory macrophages express a sub-type specific purinergic receptor profile.

Purinergic signalling·2021

Thrombotic disorders like heart attack and stroke are major health issues. New thrombolytic therapies aim to improve clot breakdown and reduce bleeding risks for better patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Thrombotic disorders, including myocardial infarction and stroke, are primary causes of mortality and morbidity in industrialized countries.
  • Effective thrombolytic therapy is crucial for reducing infarct size, preserving cardiac function, and lowering mortality rates.
  • Current thrombolytic agents like streptokinase and urokinase can cause systemic breakdown of the hemostatic system, while more specific agents like tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) may still lead to bleeding complications at therapeutic doses.

Purpose of the Study:

  • To explore novel strategies for optimizing thrombolytic therapy by enhancing efficacy and minimizing bleeding risks.
  • To investigate advanced approaches such as synergistic combinations, modified activators, and targeted delivery systems for improved risk/benefit ratios.

Related Experiment Videos

Main Methods:

  • Review of existing thrombolytic agents and their limitations.
  • Exploration of emerging therapeutic strategies including synergistic combinations of plasminogen activators.
  • Discussion of engineered molecules such as mutants of t-PA and scu-PA, chimeric molecules, and antibody-targeted thrombolytic agents.

Main Results:

  • Synergistic combinations of plasminogen activators offer potential for improved efficacy.
  • Mutants and chimeric molecules of t-PA and scu-PA aim to enhance specificity and reduce bleeding.
  • Antibody-targeted thrombolytic agents present a promising approach for localized clot dissolution and modulation of clot components.

Conclusions:

  • Optimizing thrombolytic therapy requires innovative approaches to balance efficacy and safety.
  • Future directions involve developing targeted agents and synergistic combinations to improve treatment outcomes for thrombotic disorders.
  • Antibody-targeted strategies hold potential for precise delivery of fibrinolytic or antiplatelet functions to the clot site.